uniQure surged over 300% following strong 3-year data from its Huntington's trial, yet remains undervalued due to skepticism over trial size and the use of external controls. AMT-130's apparent efficacy and prior alignment with the FDA on accelerated approval position AMT-130 for commercialization in the near term. Relatively modest volumes are needed to justify uniQure's current valuation, mea...
In one of the most incredible single-day moves this year, biotechnology stock uniQure NASDAQ: QURE surged by 284% on Sept. 24. This came as the firm released fantastic clinical results for its developmental medicine, AMT-130.
LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 6,736,841 ordinary shares at a public offering price of $47.50 per share, which includes 947,368 ordinary s...
LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 5,789,473 ordinary shares at a public offering price of $47.50 per share, and, in lieu of ordinary shares t...
UniQure announced groundbreaking results for AMT-130, its gene therapy targeting Huntington's disease, showing a statistically significant 75% reduction in disease progression in a pivotal Phase I/II trial. ((UniQure's Press Release, Sep 24, 2025)) This milestone marks the first therapy to meaningfully slow Huntington's progression and positions UniQure to unlock value across revenue growth, ma...
uniQure N.V. achieved a 75% statistically significant slowing of Huntington's Disease progression with AMT-130 in a pivotal phase 1/2 study. Plan for a pre-BLA meeting with the FDA in H2 2025, targeting a BLA filing for AMT-130 in Q1 2026 and potential Priority Review Designation if granted. With no approved disease-modifying therapies for HD and a $4.27B market opportunity, AMT-130 could trans...
LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced a $200 million underwritten public offering of its ordinary shares and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase its ...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.